NEW YORK – AstraZeneca and Daiichi Sankyo on Wednesday said they have begun three new Phase III trials to test the activity of the Trop2-targeted antibody-drug conjugate datopotamab deruxtecan ...
A health ministry panel of experts on July 31 endorsed the plan for Daiichi Sankyo Co. to begin producing and distributing the vaccine, which creates immunity for the conventional strain of the virus.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback